Study to Evaluate the Efficacy, Safety and Tolerability of MAS825 in Patients With Monogenic IL-18 Driven Autoinflammatory Diseases, Including NLRC4-GOF, XIAP Deficiency, or CDC42 Mutations

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2020
This study is a Phase 2 trial designed to evaluate the clinical efficacy, safety, and tolerability of MAS825 in patients with NLRC4-GOF, XIAP deficiency, or CDC42 mutations.
Epistemonikos ID: b92a98c277b6f174f92775ca261cc4445595c92d
First added on: Oct 02, 2023